In this article:
Blurbs

Amicus (FOLD) Receives a Hold from Leerink Partners

In this article:
In this article:

Leerink Partners analyst Joseph Schwartz reiterated a Hold rating on Amicus (FOLDResearch Report) yesterday. The company’s shares closed last Tuesday at $9.26, close to its 52-week low of $8.60.

According to TipRanks.com, Schwartz is a 3-star analyst with an average return of 2.5% and a 41.3% success rate. Schwartz covers the Healthcare sector, focusing on stocks such as Applied Molecular Transport, Ultragenyx Pharmaceutical, and Crinetics Pharmaceuticals.

Amicus has an analyst consensus of Moderate Buy, with a price target consensus of $16.25, implying a 74.9% upside from current levels. In a report issued on January 5, Berenberg Bank also maintained a Hold rating on the stock with a $14.00 price target.

See today’s best-performing stocks on TipRanks >>

Based on Amicus’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $79.55 million and GAAP net loss of $50.29 million. In comparison, last year the company earned revenue of $67.44 million and had a GAAP net loss of $64.01 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Amicus Therapeutics, Inc. engages in the discovery, development, and commercialization of novel treatments for patients living with rare and orphan diseases. Its product include migalastat HCl, which is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for fabry disease. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ.

Read More on FOLD:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More